Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker?

Key Points Eli Lilly and Viking Therapeutics both operate in the high-growth field of obesity drugs. This market is forecast to reach almost $100 billion by the end of the decade. 10 stocks we like better than Eli Lilly › Pharmaceutical giant Eli Lilly (NYSE: LLY) and biotech Viking Therapeutics (NASDAQ: VKTX) have one major thing in common: They both work in the high-growth area of weight loss drugs. Lilly's tirzepatide, sold as Mounjaro for type 2 diabetes and as Zepbound for weight loss, is brin ...